Publication | Closed Access

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma

Hematological MalignancyOncologyTransplantationMucosal DamageMedicineImmunologyHematologyMultiple MyelomaPharmacotherapyHigh-dose Melphalan ConditioningImmunotherapyPharmacologyCell TransplantationMyelopoiesis